Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

Published:2022-02 Issue:2 Volume:28 Page:315-324
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Derosa Lisa^ORCID,Routy Bertrand^ORCID,Thomas Andrew Maltez^ORCID,Iebba Valerio,Zalcman Gerard^ORCID,Friard Sylvie,Mazieres Julien^ORCID,Audigier-Valette Clarisse,Moro-Sibilot Denis^ORCID,Goldwasser François,Silva Carolina Alves Costa,Terrisse Safae,Bonvalet Melodie^ORCID,Scherpereel Arnaud,Pegliasco Hervé,Richard Corentin,Ghiringhelli François^ORCID,Elkrief Arielle,Desilets Antoine^ORCID,Blanc-Durand Felix,Cumbo Fabio,Blanco Aitor^ORCID,Boidot Romain^ORCID,Chevrier Sandy,Daillère Romain,Kroemer Guido^ORCID,Alla Laurie,Pons Nicolas,Le Chatelier Emmanuelle^ORCID,Galleron Nathalie,Roume Hugo,Dubuisson Agathe^ORCID,Bouchard Nicole,Messaoudene Meriem,Drubay Damien^ORCID,Deutsch Eric^ORCID,Barlesi Fabrice,Planchard David,Segata Nicola^ORCID,Martinez Stéphanie,Zitvogel Laurence^ORCID,Soria Jean-Charles,Besse Benjamin

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-021-01655-5.pdf

Reference63 articles.

1. Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540–1550 (2016).

2. Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015).

3. Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015).

4. Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078–2092 (2018).

5. Paz-Ares, L. et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N. Engl. J. Med. 379, 2040–2051 (2018).

Cited by 208 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Akkermansia muciniphila and herbal medicine in immune-related diseases: current evidence and future perspectives;Frontiers in Microbiomes;2024-02-05

2. Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non–small cell lung cancer;Frontiers in Immunology;2024-02-01

3. Astaxanthin exerts an adjunctive anti-cancer effect through the modulation of gut microbiota and mucosal immunity;International Immunopharmacology;2024-02

4. Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy;eBioMedicine;2024-02

5. First-line immunotherapy in non-small cell lung cancer: how to select and where to go;Expert Review of Respiratory Medicine;2024-01-31